# A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

> **NCT05117476** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Cullinan Therapeutics Inc.** · enrollment: 440 (estimated)

## Conditions studied

- Advanced Solid Tumor
- NSCLC

## Interventions

- **DRUG:** CLN-619
- **DRUG:** Pembrolizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin AUC 6
- **DRUG:** pemetrexed
- **DRUG:** Datopotamab deruxtecan-dlnk (Dato-DXd)

## Key facts

- **NCT ID:** NCT05117476
- **Lead sponsor:** Cullinan Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-29
- **Primary completion:** 2026-03
- **Final completion:** 2026-06
- **Target enrollment:** 440 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05117476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05117476, "A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05117476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*